Regen BioPharma, Inc.
RGBP
$0.00
$0.00-50.00%
OTC PK
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| SG&A Expenses | 881.80K | 843.60K | 563.30K | 503.80K | 538.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.11M | 1.07M | 575.00K | 537.40K | 604.60K |
| Operating Income | -869.20K | -828.80K | -338.60K | -300.90K | -368.10K |
| Income Before Tax | -715.80K | -1.73M | -1.27M | -972.80K | -935.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.72 | -1.73 | -1.27 | -0.97 | -0.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -715.80K | -1.73M | -1.27M | -972.80K | -935.60K |
| EBIT | -869.20K | -828.80K | -338.60K | -300.90K | -368.10K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.03 | -0.03 | -0.15 | -0.16 | -0.17 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.09 | -0.10 | -0.11 |
| EPS Diluted | -0.03 | -0.03 | -0.15 | -0.16 | -0.17 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.09 | -0.10 | -0.11 |
| Average Basic Shares Outstanding | 341.33M | 177.94M | 82.44M | 58.45M | 43.13M |
| Average Diluted Shares Outstanding | 341.33M | 177.94M | 82.44M | 58.45M | 43.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |